Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Debate JudgeSell
Generated at:2026-03-14 05:49:59
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-03-13
  • The technical breakdown indicates a significant shift in market sentiment that is likely to override positive fundamentals
  • Furthermore, the high-volume selling suggests larger, smarter money is moving out, not just retail panic
  • Moreover, the accelerating negative momentum and confirmed breakdown signal institutional distribution
  • Additionally, the 26.6% decline breaking below all major moving averages represents a trend change, not healthy consolidation
  • Most importantly, the risk of further substantial downside from the current $187.85 level is too high to justify holding
  • Therefore, it's better to exit now and potentially re-enter at a more technically stable and fundamentally justified price point
Bear Case
  • Trailing PE of -103 and forward PE of -168 showing extreme valuation concerns
  • $208 million cash burn indicating unsustainable financial performance
  • Q4 profit appears to be a fluke rather than an established trend
  • Confirmed technical breakdown with accelerating negative momentum
  • High-volume selling suggesting institutional distribution
  • Stock down 26.6% and breaking below all major moving averages
  • Technical picture indicates a trend change rather than healthy consolidation
Bull Case
  • Q4 represents a turning point toward profitability after hypergrowth scaling
  • 40% YoY revenue growth demonstrating exceptional performance
  • Expanding 64.75% gross margin showing improving operational efficiency
  • Guidance for 30%+ CAGR indicating strong future growth prospects
  • Current P/S of 11.55x considered fair price for this growth level
  • Strong balance sheet with current ratio of 3.39 to fund operations
  • Technical weakness dismissed as healthy consolidation after massive run-up

Price Targets

Analysis Summary

📊 Target Price Analysis:

  • 1-Month Target (Bearish): $165 - $170. This aligns with the estimated average cost basis from the technical report, a common psychological support level during sell-offs.
  • 3-Month Target (Baseline): $145 - $160. This reflects a further derating of the P/S multiple on slowing momentum and a test of the wider 90% cost range support ($137.69). The negative MACD and breakdown suggest this is the most probable scenario.
  • 6-Month Target (Optimistic Recovery Scenario): $210 - $230. This assumes the company reports another strong quarter (Q1 2026), confirming the path to profitability, and the technical picture repairs itself. This is a re-test of the previous support (now resistance) zone and the 20-day MA area. This is not my base case but represents the optimistic upside if the bulls are ultimately correct.

Conservative/Bear Case Scenario (High Probability): The technical downtrend continues. The stock breaks $185 and trends down towards the $165 support. If that fails, a move toward the $137-$145 range is possible. Time horizon: 1-3 months. Baseline Scenario (Most Likely): The stock finds temporary support near $165-$170 (average cost basis) but struggles to regain momentum, oscillating in the $160-$190 range for the next quarter as investors wait for fundamental confirmation from the next earnings report. Time horizon: 3-6 months. Optimistic/Bull Case Scenario (Lower Probability): The Q4 earnings prove to be a true inflection point. The next quarterly report in May shows continued margin expansion and profitability, shocking the market and reversing the technical downtrend, allowing for a grind back toward the $220+ level. Time horizon: 6+ months.

Action Strategy

Strategy Summary
  1. For current holders: Execute a sell order on any open positions. Given the weak technicals, a market order is acceptable to ensure execution.
  1. Set a buy-back alert: Monitor the stock for a potential re-entry point. We want to see a confirmed stabilization—a reclaiming of the 60-day MA (~$199) and a positive turn in the MACD histogram—before considering a new long position.
  2. Alternative for hesitant holders: If completely unwilling to sell, implement a strict stop-loss order immediately at $185, just below the lower Bollinger Band support. This defines your risk.
AI Bull vs AI Bear
Round-by-round arguments

Round 1 - Bear case

  • Natera's Q4 profitability is an unsustainable anomaly, with a trailing PE of -103.56 and a forward PE of -168.14 indicating greater future losses. It burned $208 million in 2025. Zenith Genomics faces a challenging rare disease market and is not a near-term revenue driver. Valuation is extreme with a P/S of 11.55x and P/B of 25.42x. The stock is in a confirmed downtrend, trading below all major moving averages with accelerating negative momentum and high-volume institutional selling.

Detail Preview

Alright, let's cut through the optimism and look at the cold, hard reality of Natera. While the bullish narrative is dressed up in the fancy clothes of "innovation" and "growth," the foundation is cracking. The current price of $187.85 isn't a buying opportunity; it's a warning siren. Let's break down exactly why. Refuting the Bullish "Growth Story" and "Inflection Point" The bulls are celebrating the Q4 earnings bea…

Round 2 - Bear case

  • Natera’s profitability is refuted by a negative trailing and forward P/E, signaling expected widening losses and a $208M cash burn in 2025. The technical downtrend is a confirmed breakdown, with the stock down 26.6% and showing accelerating bearish momentum. Its competitive moat is challenged in a crowded space, and new launches are capital-intensive without near-term revenue. Stratospheric valuation multiples are unsustainable for an unprofitable company.

Detail Preview

Alright, let's cut through the optimism here. While my bullish colleague paints a picture of unstoppable hypergrowth, I see a company perched on a precarious valuation cliff, facing severe headwinds that the market is finally starting to price in. Let's start by directly refuting this notion of "scaling toward profitability." A single quarter of net income—a mere $0.35 per share—does not erase a fundamental truth: th…

Round 1 - Bull case

  • Natera demonstrates hypergrowth scaling toward profitability, marked by Q4 net income of $0.35/share (+175% surprise) and revenue growth of 40% YoY. Its expanding gross margin of 64.75% shows powerful operating leverage. Its competitive moat is widened by Signatera's clinical data and the capital-efficient launch of Zenith Genomics. High valuation metrics are deemed inappropriate for a disruptive, asset-light growth company reinvesting in future earnings potential. The technical downtrend is seen as healthy consolidation and profit-taking, not fundamental deterioration.

Detail Preview

Alright, let's address these bearish points head-on. While my colleague focuses on short-term noise and traditional valuation metrics that don't capture disruptive growth stories, I see a fundamentally different picture emerging for Natera. Growth Potential: This Isn't Just Growth—It's Hypergrowth Scaling at an Inflection Point Let's be clear: Natera isn't just growing; it's fundamentally scaling its business model t…

Round 2 - Bull case

  • Q4's $208M loss is backward-looking
  • its positive net income and +175% earnings beat demonstrate new, scalable profitability. The pullback is healthy consolidation, not a breakdown. Its 11.55x P/S is justified by 40% YoY revenue growth, a 64.75% margin, and a 30%+ revenue CAGR guide. Its moat is its dominant Signatera clinical data and new Zenith Genomics TAM expansion. Its 3.39 current ratio shows a strong balance sheet.

Detail Preview

Of course. Let's dive in. I appreciate the bearish perspective—it highlights important risks that any investor must consider. However, I believe it focuses too heavily on trailing metrics and short-term technical noise, missing the profound fundamental transformation happening at Natera. Let me address your points directly and build the bullish case. Refuting the Bearish Arguments: A Fundamental Rebuttal You call the…

Round 1 - Bear case

  • Natera's Q4 profitability is an unsustainable anomaly, with a trailing PE of -103.56 and a forward PE of -168.14 indicating greater future losses. It burned $208 million in 2025. Zenith Genomics faces a challenging rare disease market and is not a near-term revenue driver. Valuation is extreme with a P/S of 11.55x and P/B of 25.42x. The stock is in a confirmed downtrend, trading below all major moving averages with accelerating negative momentum and high-volume institutional selling.

Detail Preview

Alright, let's cut through the optimism and look at the cold, hard reality of Natera. While the bullish narrative is dressed up in the fancy clothes of "innovation" and "growth," the foundation is cracking. The current price of $187.85 isn't a buying opportunity; it's a warning siren. Let's break down exactly why. Refuting the Bullish "Growth Story" and "Inflection Point" The bulls are celebrating the Q4 earnings bea…

Round 1 - Bull case

  • Natera demonstrates hypergrowth scaling toward profitability, marked by Q4 net income of $0.35/share (+175% surprise) and revenue growth of 40% YoY. Its expanding gross margin of 64.75% shows powerful operating leverage. Its competitive moat is widened by Signatera's clinical data and the capital-efficient launch of Zenith Genomics. High valuation metrics are deemed inappropriate for a disruptive, asset-light growth company reinvesting in future earnings potential. The technical downtrend is seen as healthy consolidation and profit-taking, not fundamental deterioration.

Detail Preview

Alright, let's address these bearish points head-on. While my colleague focuses on short-term noise and traditional valuation metrics that don't capture disruptive growth stories, I see a fundamentally different picture emerging for Natera. Growth Potential: This Isn't Just Growth—It's Hypergrowth Scaling at an Inflection Point Let's be clear: Natera isn't just growing; it's fundamentally scaling its business model t…

Round 2 - Bear case

  • Natera’s profitability is refuted by a negative trailing and forward P/E, signaling expected widening losses and a $208M cash burn in 2025. The technical downtrend is a confirmed breakdown, with the stock down 26.6% and showing accelerating bearish momentum. Its competitive moat is challenged in a crowded space, and new launches are capital-intensive without near-term revenue. Stratospheric valuation multiples are unsustainable for an unprofitable company.

Detail Preview

Alright, let's cut through the optimism here. While my bullish colleague paints a picture of unstoppable hypergrowth, I see a company perched on a precarious valuation cliff, facing severe headwinds that the market is finally starting to price in. Let's start by directly refuting this notion of "scaling toward profitability." A single quarter of net income—a mere $0.35 per share—does not erase a fundamental truth: th…

Round 2 - Bull case

  • Q4's $208M loss is backward-looking
  • its positive net income and +175% earnings beat demonstrate new, scalable profitability. The pullback is healthy consolidation, not a breakdown. Its 11.55x P/S is justified by 40% YoY revenue growth, a 64.75% margin, and a 30%+ revenue CAGR guide. Its moat is its dominant Signatera clinical data and new Zenith Genomics TAM expansion. Its 3.39 current ratio shows a strong balance sheet.

Detail Preview

Of course. Let's dive in. I appreciate the bearish perspective—it highlights important risks that any investor must consider. However, I believe it focuses too heavily on trailing metrics and short-term technical noise, missing the profound fundamental transformation happening at Natera. Let me address your points directly and build the bullish case. Refuting the Bearish Arguments: A Fundamental Rebuttal You call the…

End of debate